These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33402201)

  • 1. Association of Aβ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [
    O'Dell RS; Mecca AP; Chen MK; Naganawa M; Toyonaga T; Lu Y; Godek TA; Harris JE; Bartlett HH; Banks ER; Kominek VL; Zhao W; Nabulsi NB; Ropchan J; Ye Y; Vander Wyk BC; Huang Y; Arnsten AFT; Carson RE; van Dyck CH
    Alzheimers Res Ther; 2021 Jan; 13(1):11. PubMed ID: 33402201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
    Mecca AP; Chen MK; O'Dell RS; Naganawa M; Toyonaga T; Godek TA; Harris JE; Bartlett HH; Zhao W; Nabulsi NB; Wyk BCV; Varma P; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    Alzheimers Dement; 2020 Jul; 16(7):974-982. PubMed ID: 32400950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of synthetic PET images of synaptic density and amyloid from
    Wang R; Liu H; Toyonaga T; Shi L; Wu J; Onofrey JA; Tsai YJ; Naganawa M; Ma T; Liu Y; Chen MK; Mecca AP; O'Dell RS; van Dyck CH; Carson RE; Liu C
    Med Phys; 2021 Sep; 48(9):5115-5129. PubMed ID: 34224153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.
    Racine AM; Adluru N; Alexander AL; Christian BT; Okonkwo OC; Oh J; Cleary CA; Birdsill A; Hillmer AT; Murali D; Barnhart TE; Gallagher CL; Carlsson CM; Rowley HA; Dowling NM; Asthana S; Sager MA; Bendlin BB; Johnson SC
    Neuroimage Clin; 2014; 4():604-14. PubMed ID: 24936411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principal component analysis of synaptic density measured with [
    O'Dell RS; Higgins-Chen A; Gupta D; Chen MK; Naganawa M; Toyonaga T; Lu Y; Ni G; Chupak A; Zhao W; Salardini E; Nabulsi NB; Huang Y; Arnsten AFT; Carson RE; van Dyck CH; Mecca AP
    Neuroimage Clin; 2023; 39():103457. PubMed ID: 37422964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.
    Kumar A; Scarpa M; Nordberg A
    Alzheimers Dement; 2024 Apr; 20(4):2589-2605. PubMed ID: 38363009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [
    Vogler L; Ballweg A; Bohr B; Briel N; Wind K; Antons M; Kunze LH; Gnörich J; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Boening G; Ziegler SI; Levin J; Zwergal A; Höglinger GU; Herms J; Brendel M
    Neuroimage Clin; 2023; 39():103484. PubMed ID: 37541098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: A systematic review.
    Visser M; O'Brien JT; Mak E
    Ageing Res Rev; 2024 Feb; 94():102197. PubMed ID: 38266660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [
    Mecca AP; O'Dell RS; Sharp ES; Banks ER; Bartlett HH; Zhao W; Lipior S; Diepenbrock NG; Chen MK; Naganawa M; Toyonaga T; Nabulsi NB; Vander Wyk BC; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    Alzheimers Dement; 2022 Dec; 18(12):2527-2536. PubMed ID: 35174954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
    JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo imaging of synaptic loss in Alzheimer's disease with [18F]UCB-H positron emission tomography.
    Bastin C; Bahri MA; Meyer F; Manard M; Delhaye E; Plenevaux A; Becker G; Seret A; Mella C; Giacomelli F; Degueldre C; Balteau E; Luxen A; Salmon E
    Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):390-402. PubMed ID: 31468182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
    J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET.
    Silva-Rudberg JA; Salardini E; O'Dell RS; Chen MK; Ra J; Georgelos JK; Morehouse MR; Melino KP; Varma P; Toyonaga T; Nabulsi NB; Huang Y; Carson RE; van Dyck CH; Mecca AP
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):17-28. PubMed ID: 37673749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a difference in regional read [
    Farrar G; Molinuevo JL; Zanette M
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1299-1308. PubMed ID: 30863934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.